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he Use of Anti-Inflammatory
nalgesics in the Patient
ith Cardiovascular Disease
hat a Pain*
teven R. Steinhubl, MD, FACC
exington, Kentucky
“One of the first duties of the physician is to educate the masses
not to take medicine”
—Sir William Osler (1)
ith all of the recent news in both the medical and lay press
egarding the use of pain relievers and cardiovascular risk, a
umber of questions appropriately have been raised by both
atients and physicians. In particular, what can be done for
he patient who already has, or is at high risk for, athero-
clerotic cardiovascular disease but who also suffers from
hronic, or even just intermittent, joint aches and pains?
he magnitude of this problem can easily be underesti-
ated by the busy cardiologist focusing on a patient’s
ardiovascular symptoms and risks during office visits, but
ross-sectional studies tell us that among adults age 50 years
r older, the four-week prevalence of pain is 72.4%, with
8.1% of all individuals reporting pain severe enough to
nterfere with daily activities (2). Therefore, any possibility
f a harmful interaction between pain relievers and the
therosclerotic process, or the medicines used to prevent its
omplications, could have a potentially enormous impact on
ardiovascular risk.
See page 1295
Although the selective cyclooxygenase (COX)-2 inhibi-
ors have been the subjects of most recent attention,
onselective COX inhibitors have been recognized for
everal years now as potentially limiting the cardioprotective
ffects of aspirin. In the initial landmark study, Catella-
awson et al. (3) demonstrated that when the nonselective
OX inhibitor ibuprofen was taken before aspirin, aspirin’s
bility to inhibit serum thromboxane (TX)B2 formation and
latelet aggregation was prevented. Acetaminophen, di-
lofenac, and rofecoxib did not share this effect. The
ostulated mechanism behind this interaction is that ibu-
rofen, when taken before aspirin, blocks the platelet
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Division of Cardiovascular Medicine and the Gill Heart Institute,
niversity of Kentucky, Lexington, Kentucky. Dr. Steinhubl has served as a
onsultant for, and received research support from, Accumetrics, Inc., maker of thea
ltegra Rapid Platelet Function Assay, and the Bristol-Myers Squibb/Sanofi-Aventis
artnership, makers of clopidogrel.OX-1 catalytic site and, therefore, prevents aspirin from
ccessing the enzyme and irreversibly acetylating the serine
esidue at position 529. Normally, when aspirin is able to
cetylate platelet COX-1, the enzyme is inhibited for the
ife of the platelet. In contrast, ibuprofen, a reversible,
ompetitive COX inhibitor, is only able to inhibit COX-1
or several hours, and by 6 h thromboxane production
eturns and platelet aggregation begins to approach normal
evels. Because aspirin has a very short plasma half-life of
nly 15 to 20 min (4,5), if acetylation of COX-1 is
revented by ibuprofen during this time, acetylation cannot
ccur and platelet function will return to normal as soon as
20% of platelet COX-1 activity returns (6).
Results of this trial led to a relatively specific focus on the
otentially harmful interaction between ibuprofen and as-
irin. Other commonly used, reversible, nonselective COX
nhibitors, such as indomethacin and naproxen, were not
valuated in this study, and although there was no reason to
elieve that their effect on platelet COX-1 would be any
ifferent than that of ibuprofen, for many, a lack of evidence
or harm translated into evidence of a lack of harm. Several
linical trials suggesting a cardioprotective effect of
aproxen, in particular the widely promoted Vioxx Gastro-
ntestinal Outcomes Research (VIGOR) trial results (7),
eemed to support this view. Although conclusive evidence
f any benefit or harm is still lacking, it would be fair to say
hat the majority of primary observational data seemed to
avor a cardioprotective effect of naproxen (8), that is, until
ust recently, when the National Institutes of Health an-
ounced the suspension of the 2,400-patient Alzheimer’s
isease Anti-inflammatory Prevention Trial (ADAPT)
fter three years due to a significant increase (no event rates
ave been officially released) in cardiovascular and cerebro-
ascular events in patients randomly assigned to naproxen
ompared with placebo. This widely publicized announce-
ent has lead to even more confusion regarding the role of
aproxen in particular, and pain relievers in general, in
atients at risk for cardiovascular disease.
The study reported by Capone et al. (9) in this issue of
he Journal helps shed some light on the possibility of an
nteraction between naproxen and aspirin therapy and
echanisms on how it might influence cardiovascular
vents. First, they confirmed in vitro that naproxen revers-
bly and competitively inhibited COX-1, that this inhibition
ould be overcome by increasing concentrations of arachi-
onic acid (AA), and that aspirin was prevented from
nhibiting COX-1 in platelets pretreated with naproxen.
econd, they found that when single doses of naproxen and
spirin were given simultaneously, irreversible, long-lasting
nhibition of TXB2 and AA-induced platelet aggregation by
spirin was prevented. However, and in contrast to previous
esults with ibuprofen, chronic administration of naproxen
nd aspirin simultaneously, irrespective of whether
aproxen was taken before or after aspirin, provided similar
nd complete inhibition of serum TXB2 production, AA-
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etabolite levels for as long as 26 h after the last aspirin
ose and 12 h after the last naproxen dose. Finally, they
onfirmed that 100 mg of aspirin daily had no effect on
OX-2-dependent prostaglandin E2 production, whereas
00 mg of naproxen twice a day profoundly inhibited it.
The fact that chronic, concomitant naproxen and aspirin
herapy did not negatively influence platelet COX activity
ay seem contrary to the previous results with ibuprofen
nd suggest a different effect of naproxen, but this finding
ctually is explained by the 14-h plasma half-life of
aproxen compared with the only 2-h half-life of ibuprofen
10). Previous studies by this same group have found that
aproxen can near maximally inhibit platelet COX-1 activ-
ty for 24 h, by which time it starts to slowly recover (11).
o does this mean that if a patient takes naproxen 500 mg
wice daily, every day, that they will derive similar cardio-
rotection as that afforded by daily aspirin therapy? Possibly,
ut there are several reasons this may not be the case. First,
igh levels of AA can overwhelm the ability of naproxen,
ut not aspirin, to inhibit platelet COX-1. Theoretically,
ocal concentrations of AA at the site of vascular injury
ould be high enough to displace naproxen from the enzyme
eading to the generation of TXA2. Second, as shown in this
nd previous studies (11), naproxen, but not aspirin, inhibits
OX-2 activity and the biosynthesis of prostaglandin I2,
hich is both a vasodilator and platelet inhibitor. The
linical implications of these differences are unknown but
ighlight that naproxen and aspirin are clearly not inter-
hangeable therapies.
So what should we tell our patients who are undergoing
hronic low-dose aspirin therapy for cardioprotection and
able 1. Treatment Options to Minimize Interference With
ardioprotective Effects of Aspirin in the Patient Requiring
hort- or Long-Term Anti-Inflammatory Therapy
1. Consider acetaminophen, diclofenac, or COX-2 inhibitors.
2. Take a non-enteric coated aspirin at least 15 to 30 min (if chewed)
or 2 h (if swallowed) prior to taking a NSAID, and at least 6 to 8 h
after last dose of ibuprofen or 36 to 48 h after naproxen.
3. Consider increasing aspirin to anti-inflammatory doses (325 mg four
times daily).
4. Recommend the shortest treatment course possible.
OX  cyclooxygenase; NSAID  non-steroidal anti-inflammatory drug.equire treatment with an anti-inflammatory analgesic?everal options are listed in Table 1, but each has its
imitations. Unfortunately, only if and when adequately
owered clinical trials are conducted to establish the cardio-
ascular risks and benefits of available pain relievers will we
e able to accurately guide our patients as to what pain
eliever is safest for them to take.
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